---
title: "Quantum Hardware Expansions Accelerate While Biotech Funds Face Outflows"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294038837.md"
description: "Advanced hardware developers are rapidly scaling their North American operations, highlighted by Xanadu’s USD 300M equity program and its new New York manufacturing facility. Meanwhile, biotech funds like XBI are experiencing capital withdrawals, reflecting tactical investor rotations across innovation sectors."
datetime: "2026-07-28T09:12:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294038837.md)
  - [en](https://longbridge.com/en/news/294038837.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294038837.md)
generator: "portal-rs"
---

# Quantum Hardware Expansions Accelerate While Biotech Funds Face Outflows

As deep tech companies rapidly scale their North American manufacturing footprints—underpinned by a newly launched USD 300M equity program in the quantum computing sector—capital flows across broader innovation funds remain volatile, according to industry data and recent company filings.

### Xanadu Quantum Technologies (XNDU.US)

Xanadu Quantum Technologies (XNDU.US) is targeting an aggressive expansion of its US commercial operations. On July 9, 2026, the Toronto-based company announced a new operations center in Albany, New York, tapping into the upstate advanced semiconductor research corridor. The move aims to scale its photonic hardware manufacturing alongside partners like Applied Materials, according to company statements. To support this, Xanadu secured a USD 300M at-the-market equity program in May. The firm has increased its US-based hardware and engineering headcount fivefold since 2023, while recently achieving industry benchmarks in ultra-low edge coupling loss for photonic chip packaging.

### State Street SPDR S&P Biotech ETF (XBI.US)

Meanwhile, the State Street SPDR S&P Biotech ETF (XBI.US) has faced shifting investor sentiment against the backdrop of tech infrastructure investments. Recent reports indicate the fund has experienced notable outflows, affecting holdings such as Twist Bioscience and Kymera Therapeutics. The equal-weighted fund, carrying a 0.35% expense ratio, is designed to provide balanced exposure across biotech caps, according to July 2026 analyses. However, its performance remains heavily tethered to the sector's inherent regulatory hurdles and volatility, prompting a reshuffling of positions by institutional investors.

The contrast highlights a broader trend: while funding continues to pour into semiconductor and quantum computing hardware capable of handling next-generation AI workloads, specialized biotech funds are seeing more tactical reallocations.

*This article does not constitute investment advice.*

### Related Stocks

- [XNDU.US](https://longbridge.com/en/quote/XNDU.US.md)

## Related News & Research

- [Why Xanadu Quantum (XNDU) Surged 17% after Its S-8 Filing While RGTI, QBTS, IONQ, and HQ Fell](https://longbridge.com/en/news/287771156.md)
- [Xanadu Quantum Computing Craters on Share Listing. Why This Might Be a Buy-the-Dip Opportunity for XNDU Stock.](https://longbridge.com/en/news/285108122.md)
- [Dear Xanadu Quantum Stock Fans, Mark Your Calendars for May 14](https://longbridge.com/en/news/286139830.md)
- [Xanadu (XNDU) Stock Plunged 61%. Here Is What Investors Should Watch Next](https://longbridge.com/en/news/285201700.md)
- [Why Xanadu (XNDU) Stock Sank 68% after Its SEC Filing](https://longbridge.com/en/news/285069432.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**